share_log

HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Raises Price Target to $144

Benzinga ·  Jun 2, 2023 09:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $135 to $144.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment